Anzemet   body {font-family: 'Open Sans', sans-serif;} .ui-header .ui-title, .ui-footer .ui-title { margin-right: 0 !important; margin-left: 0 !important; } \* { margin:0px; padding:0px;} .ui-page { background: #f2f2f2 url(bg.jpg); line-height:1.5em;} #home\_link { color:#FFF; text-decoration:none; cursor:pointer; font-family:'AndikaBasicRegular',Arial, sans-serif; font-size:0.9em; margin-left:15%; } #home\_link span {font-size:0.6em;margin-left:15%; color: #D8D8D8; } h1 {font-family:'AndikaBasicRegular'; }

# Anzemet

**Anzemet (Dolasetron)**  
**Class:** anti-nauseant and antiemetic agent.  
Highly specific and selective serotonin subtype 3 (5-HT3) receptor antagonist.  
Not nearly as popular as Zofran.  
More popular for to preventing nausea before chemotherapy.  
**Doses:**  
12.5 mg IV 15 minutes before the cessation of anesthesia.  
(prevention) or as soon as nausea or vomiting presents (treatment).  
**Peds:** 2 to 16 years of age is 0.35 mg/kg, with a maximum dose of 12.5 mg.  
**Like Zofran-** The FDA also previously noted cardiovascular safety concerns which suggested Anzemet could cause QT prolongation.  
**RECOMMENDATION:**  
Avoid ANZEMET in patients with congenital long QT syndrome, hypokalemia or hypomagnesemia.  
Serotonin receptors of the 5-HT3 type are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema.  
**MOA:**  
During chemotherapy-induced vomiting, mucosal enterochromaffin cells release serotonin, which stimulates 5-HT3 receptors. This evokes vagal afferent discharge and may induce vomiting.  
Studies demonstrate that, in binding to 5-HT3 receptors, Anzemet blocks serotonin stimulation and subsequent vomiting after emetogenic stimuli such as cisplatin.

#### Copyright Â© 2012